No black box warning on record for Saphnelo

As of the latest FDA labeling reviewed, Saphnelo (ANIFROLUMAB-FNIA) does not carry a black box warning. Standard warnings and precautions still apply — see the full Saphnelo medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Serious Infections: Serious and sometimes fatal infections have occurred in patients receiving SAPHNELO. SAPHNELO increases the risk of respiratory infections and herpes zoster. Avoid initiating treatment during an active infection. Consider the individual benefit-risk if using in patients with severe or chronic infections. Consider interrupting therapy with SAPHNELO i

No black box warning on record for Saphnelo

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Serious Infections: Serious and sometimes fatal infections have occurred in patients receiving SAPHNELO. SAPHNELO increases the risk of respiratory infections and herpes zoster. Avoid initiating treatment during an active infection. Consider the individual benefit-risk if using in patients with severe or chronic infections. Consider interrupting therapy with SAPHNELO i

Saphnelo Black Box Warning

No black box warning on record for Saphnelo

Other warnings & precautions

Saphnelo Black Box Warning

No black box warning on record for Saphnelo

Other warnings & precautions